RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Biomarin Pharmaceutical Stock

Biomarin Pharmaceutical Equity 2024

Biomarin Pharmaceutical Equity

4.95 B USD

Ticker

BMRN

ISIN

US09061G1013

WKN

924801

In 2024, Biomarin Pharmaceutical's equity was 4.95 B USD, a 7.57% increase from the 4.6 B USD equity in the previous year.

Biomarin Pharmaceutical Aktienanalyse

What does Biomarin Pharmaceutical do?

Biomarin Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare genetic diseases. The company was founded in 1997 and is headquartered in San Rafael, California. Biomarin Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Biomarin Pharmaceutical revenue by segment

In the annual report of the Biomarin Pharmaceutical share (US09061G1013, 924801, BMRN), it breaks down its revenues into 1 segments: 1. Development & Commercialization of Innovative Therapies. The Biomarin Pharmaceutical stock (WKN: 924801, ISIN: US09061G1013, Ticker Symbol: BMRN) is a leading investment for investors interested in participating in the Health Care sector.

  • 100 % Development & Commercialization of Innovative Therapies

Equity Details

Analyzing Biomarin Pharmaceutical's Equity

Biomarin Pharmaceutical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biomarin Pharmaceutical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biomarin Pharmaceutical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biomarin Pharmaceutical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biomarin Pharmaceutical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biomarin Pharmaceutical stock

What is the equity of Biomarin Pharmaceutical this year?

Biomarin Pharmaceutical has equity of 4.95 B USD this year.

What was the equity of Biomarin Pharmaceutical compared to the previous year?

The equity of Biomarin Pharmaceutical has increased/decreased by 7.57% increased compared to the previous year.

What impact does a high equity have on investors of Biomarin Pharmaceutical?

A high equity is advantageous for investors of Biomarin Pharmaceutical as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Biomarin Pharmaceutical?

A low equity can be a risk for investors of Biomarin Pharmaceutical, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Biomarin Pharmaceutical affect the company?

An increase in equity of Biomarin Pharmaceutical can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Biomarin Pharmaceutical affect the company?

A reduction in equity of Biomarin Pharmaceutical can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Biomarin Pharmaceutical?

Some factors that can affect the equity of Biomarin Pharmaceutical include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Biomarin Pharmaceutical so important for investors?

The equity of Biomarin Pharmaceutical is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Biomarin Pharmaceutical take to change the equity?

To change equity, Biomarin Pharmaceutical can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Biomarin Pharmaceutical pay?

Over the past 12 months, Biomarin Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biomarin Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Biomarin Pharmaceutical?

The current dividend yield of Biomarin Pharmaceutical is .

When does Biomarin Pharmaceutical pay dividends?

Biomarin Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biomarin Pharmaceutical?

Biomarin Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Biomarin Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biomarin Pharmaceutical located?

Biomarin Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biomarin Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biomarin Pharmaceutical from 9/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did Biomarin Pharmaceutical pay the last dividend?

The last dividend was paid out on 9/16/2024.

What was the dividend of Biomarin Pharmaceutical in the year 2023?

In the year 2023, Biomarin Pharmaceutical distributed 0 USD as dividends.

In which currency does Biomarin Pharmaceutical pay out the dividend?

The dividends of Biomarin Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Biomarin Pharmaceutical stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Biomarin Pharmaceutical

Our stock analysis for Biomarin Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomarin Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.